2026 · FINDING
CITEDTRIUMPH Phase 3 topline (obesity)
28.7% mean body-weight reduction at 48 weeks, 12mg weekly. Highest weight-loss result ever recorded in a phase 3 obesity trial.
⚠ RESEARCH USE ONLY · NOT FDA-APPROVED FOR HUMAN USE · NOT MEDICAL ADVICE
TRENDINGPHASE 3 TRIALS
Retatrutide.
The Triple Threat
AKA · Triple G · LY3437943
TRENDINGWEIGHT LOSSSUBCUTANEOUS
Triple agonist hitting GLP-1, GIP, and glucagon receptors. April 2026 Phase 3 TRIUMPH data: 28.7% mean weight loss — highest ever recorded in an obesity trial. Lilly expected to file NDA in Q4 2026.
~6 days (estimated from Phase 2 data)
Half-life
5
Citations
1
Routes
2
Categories
Research
Storage
85
Popularity
AT A GLANCE.
§ 01 · TL;DRTHE QUICK READ.
Triple agonist hitting GLP-1, GIP, and glucagon receptors. April 2026 Phase 3 TRIUMPH data: 28.7% mean weight loss — highest ever recorded in an obesity trial. Lilly expected to file NDA in Q4 2026.
Activates THREE receptors: GLP-1 for appetite, GIP for insulin response, glucagon for thermogenic fat-burning.
WHAT IT MIGHT HELP WITH.
1
28.7% mean weight loss at 48 weeks (TRIUMPH Phase 3, 2026) — highest ever recorded
2
Up to 71.2 lbs average loss at top dose
3
Significant A1C reduction (−2.0%) in T2D trial
4
Reported osteoarthritis pain relief in TRIUMPH-OA arm
5
Up to 86% liver fat reduction in NAFLD subgroup
6
Triple mechanism may preserve lean mass better than pure GLP-1
HOW IT WORKS.
§ 02 · MECHANISMActivates THREE receptors: GLP-1 for appetite, GIP for insulin response, glucagon for thermogenic fat-burning.
Triple agonism of GLP-1/GIP/glucagon provides appetite suppression, improved glucose handling, AND increased energy expenditure via glucagon's thermogenic effects. The glucagon arm is what separates it from tirzepatide and drives the record-breaking weight-loss numbers.
WHO IT'S FOR
- ✓Cutting-edge weight loss seekers
- ✓Research compound enthusiasts
- ✓Biohackers
WHO SHOULD AVOID
- ✕Those needing FDA-approved meds
- ✕Risk-averse individuals
- ✕Pregnant/planning
THE RESEARCH.
§ 03 · 5 STUDIES2026 · FINDING
CITEDTRANSCEND-T2D-1 (diabetes)
A1C reductions up to −2.0% in type 2 diabetes patients; significant weight loss alongside glycemic control.
2023 · FINDING
CITEDPhase 2 foundational trial
24.2% body weight reduction at 48 weeks; dose-response signal that set expectations for Phase 3.
2024 · FINDING
CITEDNAFLD/NASH substudy
Up to 86% reduction in liver fat in patients with non-alcoholic fatty liver disease.
2026 · FINDING
TRIUMPH-OA (osteoarthritis)
Substantial relief from osteoarthritis pain alongside weight loss — first Phase 3 weight-loss drug to demonstrate this.
DOSING PROTOCOL.
§ 04 · DOSINGTYPICAL RANGE
Research reported dose
Phase 3 testing doses up to 12mg weekly
FREQUENCY
Most-cited schedule
Once weekly
ROUTES
Delivery methods
SUBCUTANEOUS
HALF-LIFE
Steady state drives frequency
~6 days (estimated from Phase 2 data)
STORAGE
Protect from light, refrigerate
Research protocols specify
⚠ NOTE
These are reported protocols from research literature and practitioner accounts, not prescriptions. No FDA-approved human dose exists for research compounds. Anyone using Retatrutide should work with a qualified physician and source from a supplier providing third-party COAs.
FORMS AVAILABLE
- · Subcutaneous injection
⚠ RESEARCH INFORMATION ONLY · NOT MEDICAL ADVICE
SIDE EFFECTS & RISKS.
§ 06 · SAFETY·
Nausea
Common · mild
·
Diarrhea
Common · mild
·
Vomiting
Common · mild
WHERE TO SOURCE
§ 07 · SUPPLIERPEAK LAB
PEPTIDES
PEPTIDES
SUPPLIER OF RECORD · 12 BATCHES PASSED
We tried nine suppliers across 2025 and kept picking PEAK LAB for Retatrutide: 99.4% HPLC purity, COA on every batch, cold chain intact. Shop through our link and we earn a small commission — affiliate relationship is disclosed.
COMMON QUESTIONS.
§ 08 · FAQWhen might retatrutide receive FDA approval?
Phase 3 trials are ongoing as of 2024. Based on typical timelines, FDA review could occur 2025-2026 if trials are successful, though regulatory timelines vary.
How does the glucagon receptor component help?
Research indicates glucagon activation increases energy expenditure and promotes fat oxidation, potentially explaining the superior weight loss compared to dual agonists.
What about the liver fat reduction findings?
Phase 2 data showed remarkable hepatic fat reduction (up to 86%), suggesting potential applications for fatty liver disease. This is being studied in dedicated trials.
Is it safe to obtain outside clinical trials?
Retatrutide is not approved for human use and obtaining it outside trials means using unregulated products of unknown quality and safety. Research-only compounds carry significant risks.
MORE ON RETATRUTIDE.
§ 10 · FIELD NOTES◆ Research Updates · ★ FEATURE
Retatrutide Phase 3: The 28.7% Number, In Context
Lilly's triple agonist just posted the highest weight-loss result ever recorded in a Phase 3 obesity trial. Here's what TRIUMPH actually showed — and what it didn't.
9 min·READ →
◆ Sourcing
Compounded Semaglutide In 2026: What Changed, What's Next
The FDA removed semaglutide from shortage in early 2025. Compounding pharmacies scrambled. Legal battles followed. Here is what actually happened and what to do.
8 min·READ →
◆ Research Updates
Survodutide And The Liver: A Dual Agonist's Specific Niche
Boehringer Ingelheim is betting that GLP-1/glucagon dual agonism is the answer for MASH — and the Phase 3 data is coming in 2026.
7 min·READ →
◆ THE PEPGAINS DISPATCH
GET THE NEXT UPDATE FIRST.
New research on Retatrutide + a weekly dispatch on everything else moving in the peptide world. One email. Unsubscribe in a click.